Last reviewed · How we verify

gemcitabine/Eloxatin (GEMOX)

Sanofi · Phase 3 active Small molecule

Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinks.

Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinks. Used for Pancreatic cancer, Biliary tract cancer.

At a glance

Generic namegemcitabine/Eloxatin (GEMOX)
SponsorSanofi
Drug classplatinum-based chemotherapeutic agent and nucleoside analog
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Gemcitabine works by inhibiting DNA synthesis through its incorporation into DNA, which leads to cell death. Oxaliplatin, on the other hand, forms platinum-DNA adducts, causing DNA damage and triggering cell death. The combination of these two agents in GEMOX is thought to enhance the efficacy of chemotherapy by targeting cancer cells through multiple mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: